Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s JUPITER Study Brings Challenges For Crestor Marketing

Executive Summary

AstraZeneca and its cholesterol-lowering agent Crestor scored a clear coup Nov. 9, when results of the widely-publicized JUPITER trial were announced at the American Heart Association meeting. The firm's ability to maximize the potential of the findings, however, presents multiple marketing challenges

You may also be interested in...



Crestor Helps Shelter AstraZeneca From Economic Storm

Unlike other Big Pharmas, firm also gets a temporary reprieve from generic erosion of two brands.

Insurers View JUPITER With Caution; Can Benefit Be Achieved With Generics?

As insurers begin to review the details of AstraZeneca's headline-making outcomes study on Crestor - the JUPITER trial - a key question is whether the benefit found can also be extrapolated to less expensive statins, including generics

Will JUPITER Change Statin Use?

Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.

Related Content

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel